Skip to main content

Table 3 Mean Doxorubicin distribution in xenografts

From: Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib

Tumour type and treatment Distance from blood vessel at which fluorescence falls to 50% its original value (L) Doxorubicin distribution (μm × I) Microvascular Density
HCT-8Ea 24 ± 5 785 ± 190 3.0 ±0.5
HCT-8Ra 31 ± 6 1476 ± 370* 6.0 ± 0.8
HCT-8Ea & Bortezomib pre-treatment 29 ±7 1140 ± 190* 2.6 ± 0.3
HCT-8E11 29 ± 8 990 ± 220 4.1 ± 0.4
HCT-81R1 43 ± 11 2097 ± 248** 2.8 ± 0.2
HCT-8E11 & Bortezomib pre-treatment 35 ± 9 1170 ± 200** 3.8 ± 0.6
  1. Drug distribution is represented by the area under the curve representing doxorubicin intensity vs. distance from the nearest blood vessel up to 100 μm. Data were obtained from 10-12 animals and represent mean ± packing density. The distance from blood vessel at which fluorescence falls to 50% its original value (L), presented as mean ± standard deviation was significantly greater in the HCT-8 Ra and 1R1 xenografts than that observed in HCT-8 Ea and E11 tumours (p = 0.003 for HCT-8Ra and Ea and p = 0.008 for HCT-81R1 and E11 tumour xenografts; paired T-tests). This distance was greater in tumor xenografts pre-treated with bortezomib (p = 0.035 and p = 0.048 in HCT-8Ea and HCT-8E11 tumour xenografts pre-treated with bortezomib) than in control.
  2. * p≤0.05 for comparison with HCT-8Ea tumor xenografts.
  3. ** p≤0.05 for comparison with HCT-8E11 tumor xenografts.